A$3.38 after hours AYA.AX Artrya Limited ASX 09 Feb 2026: AI imaging catalyst

AYA.AX stock opened the after-hours session at A$3.38 on 09 Feb 2026, a price that places Artrya Limited well below its 52-week high A$5.24 but above the 200-day average of A$2.34. Investors tracking AI health-imaging plays will note mixed signals: strong technical momentum and a small market capitalisation of A$370,556,400.00, against negative earnings per share of -0.17 and a negative price-to-earnings ratio of -19.24. This update covers valuation, technicals, Meyka AI grading, and model-led price forecasts that frame short- and medium-term opportunity and risk for AYA.AX stock.

AYA.AX stock snapshot and trading facts

AYA.AX stock last traded at A$3.38 after hours on 09 Feb 2026. The intraday range was A$3.30 to A$3.54, with volume at 351,719.00 and average volume 766,167.00.

Market structure is small-cap on the ASX, with 113,320,000.00 shares outstanding and market capitalisation of A$370,556,400.00. Artrya operates in healthcare AI, selling the Salix imaging platform that automates coronary CT scan analysis.

AYA.AX stock financials and valuation

The company reports negative profitability with EPS -0.17 and PE -19.24, reflecting a scale-up phase. Key balance metrics show high liquidity, with current ratio 8.27 and cash per share A$0.11.

Valuation multiples look stretched relative to revenue: price-to-sales is 13,234.16 and price-to-book 15.83. These figures signal investor pricing for future AI growth rather than today’s revenue, increasing sensitivity to execution.

Technicals and trading signals for AYA.AX stock

Momentum indicators show short-term strength: RSI 70.89 (near overbought) and ADX 40.86 indicating a strong trend. Moving averages show 50-day A$4.04 above 200-day A$2.34, but price sits under the 50-day average.

Volume metrics show relative liquidity: on-session volume 351,719.00 versus average 766,167.00, a relative volume of 0.72. Traders should watch RSI, the A$3.23 Bollinger lower band, and MACD histogram 0.09 for pullback signals.

Meyka AI grade, model forecast and price outlook

Meyka AI rates AYA.AX with a score out of 100: 63.20 | Grade B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a monthly price of A$3.56, a quarterly price of A$5.83, and a yearly price of A$7.90. Compared with the current A$3.38, the model implies a near-term upside of 5.33% to the monthly view, 72.49% to the quarterly view, and 133.70% to the yearly view. Forecasts are model-based projections and not guarantees.

Risks and sector context for AYA.AX stock

Artrya sits in Healthcare on the ASX where sector PE averages near 32.06 and investors reward profitability and scale. Artrya’s negative margins and very high price-to-sales multiple elevate execution risk.

Specific risks include regulatory adoption cycles, reimbursement timing, and revenue concentration. Balance-sheet strength limits short-term financing risk, but stock volatility and low liquidity can amplify moves on news.

Analyst view, price targets and trading strategy

Analyst consensus data is thin. Given the model output, a staged price-target framework is reasonable: conservative target A$5.50, model-driven target A$7.90, and upside case A$12.00 if adoption accelerates. Use a risk-managed approach: scale in on measurable revenue wins and regulatory milestones.

For active traders, monitor earnings announcement scheduled 24 Feb 2026 and short-term technicals. Longer-term investors should demand recurring revenue growth and margin improvement before increasing exposure.

Final Thoughts

Key takeaways for AYA.AX stock: Artrya Limited trades at A$3.38 after hours on 09 Feb 2026 with a market cap of A$370,556,400.00 and negative EPS -0.17, reflecting an early-stage AI healthcare business. Technical indicators show strength but potential overbought conditions. Meyka AI rates AYA.AX 63.20 (B) and flags a HOLD while the model highlights meaningful upside. Specifically, Meyka AI’s forecast model projects a yearly price of A$7.90, implying 133.70% upside from A$3.38. Investors should weigh that model upside against high valuation multiples, negative margins, and adoption risk. We see a structured trade framework: monitor the 50-day average A$4.04, upcoming earnings on 24 Feb 2026, and any commercial contract announcements. Meyka AI, an AI-powered market analysis platform, recommends position sizing that reflects high volatility and execution risk. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.